Biapenem

Biapenem
Clinical data
Trade names	Omegacin, Bianem
AHFS/Drugs.com	International Drug Names
Routes of; administration	IV
ATC code	J01DH05 (WHO) ;
Legal status
Legal status	In general: ℞ (Prescription only);
Identifiers
	IUPAC name (4R,5S,6S)-3-(6,7-Dihydro-5H-pyrazolo[1,2-a][1,2,4]triazol-8- ium-6-ylsulfanyl)-6-(1-hydroxyethyl)- 4-methyl-7-oxo-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate;
CAS Number	120410-24-4 ;
PubChem CID	71339;
ChemSpider	64442 ;
UNII	YR5U3L9ZH1;
ChEBI	CHEBI:3089 ;
ChEMBL	ChEMBL285347 ;
CompTox Dashboard (EPA)	DTXSID5046435 ;
Chemical and physical data
Formula	C15H18N4O4S
Molar mass	350.39 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1C2C(C(=O)N2C(=C1SC3CN4C=NC=[N+]4C3)C(=O)[O-])C(C)O;
	InChI InChI=1S/C15H18N4O4S/c1-7-11-10(8(2)20)14(21)19(11)12(15(22)23)13(7)24-9-3-17-5-16-6-18(17)4-9/h5-11,20H,3-4H2,1-2H3/t7-,8-,10-,11-/m1/s1 ; Key:MRMBZHPJVKCOMA-YJFSRANCSA-N ;
	(verify)

Biapenem (INN) is a carbapenem antibiotic sold in Japan under the brand name Omegacin,^[1] and in India as Bianem.^[2]^[3] It is a synthetic β-lactam antibiotic belonging to the carbapenems chemical class, developed by the Japanese subsidiary of Lederle Pharmaceuticals in the late 1980's.^[4]

Biapenem was approved for use in Japan in 2001, and launched to market there in 2002,^[5] with clinical trials approved in India in 2021,^[2] and full market launch later the same year.^[3] In clinical trials, it was found to be more effective at lower doses than imipenem, but less effective than equivalent doses of ceftazidime.^[4]

Medical uses

Biapenem is effective against a wide range of gram-positive and gram-negative bacteria,^[6]^[7] including Escherichia coli, Klebsiella pneumoniae, Klebsiella aerogenes, Enterobacter cloacae, Citrobacter freundii, Serratia marcescens, Proteus mirabilis, Proteus vulgaris, and Morganella morganii.^[4]

Unlike some other carbapenems, notably imipenem, biapenem is not particularly susceptible to hydrolysis by human renal dihydropeptidase-I (DHP-I), meaning it can be administered effectively without an adjunct like cilastatin.^[8]

Resistance to biapenem is similar to that of imipenem, with similar mechanisms responsible.^[9] It is most frequently given as an intravenous infusion.^[10]

References

↑ Aldridge KE, Morice N, Schiro DD (April 1994). "In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes". Antimicrobial Agents and Chemotherapy. 38 (4): 889–893. doi:10.1128/aac.38.4.889. PMC 284564. PMID 8031067.
1 2 "Permission to conduct Clinical Trial for Biapenem Injection 300 mg (Form CT-06, File No. ND/MA/21/000018)" (PDF). Central Drugs Standard Control Organization (CDSCO), Government of India. 2021-04-22. Retrieved 2026-08-04.
1 2 Sharma, Ruchika (2021-09-25). "BDR Pharma gets DCGI nod for generic antibiotic drug Biapenem". Medical Dialogues. Retrieved 2026-08-04.
1 2 3 Ubukata K, Hikida M, Yoshida M, Nishiki K, Furukawa Y, Tashiro K, et al. (June 1990). "In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I". Antimicrobial Agents and Chemotherapy. 34 (6): 994–1000. doi:10.1128/aac.34.6.994. PMC 171745. PMID 2203313.
↑ Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV (June 2013). "In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria". Antimicrobial Agents and Chemotherapy. 57 (6): 2620–2630. doi:10.1128/AAC.02418-12. PMC 3716157. PMID 23529731.
↑ Kozawa O, Uematsu T, Matsuno H, Niwa M, Takiguchi Y, Matsumoto S, et al. (June 1998). "Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects". Antimicrobial Agents and Chemotherapy. 42 (6): 1433–1436. doi:10.1128/aac.42.6.1433. PMC 105618. PMID 9624490.
↑ Sloan RW (June 1992). "Principles of drug therapy in geriatric patients". American Family Physician. 45 (6): 2709–2718. PMID 1595518.
↑ Perry CM, Ibbotson T (2002). "Biapenem". Drugs. 62 (15): 2221–34, discussion 2235. doi:10.2165/00003495-200262150-00005. PMID 12381221.
↑ Chen HY, Livermore DM (May 1994). "In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms". The Journal of Antimicrobial Chemotherapy. 33 (5): 949–958. doi:10.1093/jac/33.5.949. PMID 8089068.
↑ Hara K, Baba S, Matsumoto F, Ooishi M, Kawada Y, Arata J, et al. (November 1999). "[Clinical evaluation of biapenem in various infectious diseases]" Clinical evaluation of biapenem in various infectious diseases. The Japanese Journal of Antibiotics (in Japanese). 52 (11): 629–660. PMID 10659441.

External links

(in Japanese) Omegacin

[Aldridge_1994-1] Aldridge KE, Morice N, Schiro DD (April 1994). "In vitro activity of biapenem (L-627), a new carbapenem, against anaerobes". Antimicrobial Agents and Chemotherapy. 38 (4): 889–893. doi:10.1128/aac.38.4.889. PMC 284564. PMID 8031067.

[Permission_to_conduct_2021-2] 1 2 "Permission to conduct Clinical Trial for Biapenem Injection 300 mg (Form CT-06, File No. ND/MA/21/000018)" (PDF). Central Drugs Standard Control Organization (CDSCO), Government of India. 2021-04-22. Retrieved 2026-08-04.

[Sharma_2021-3] 1 2 Sharma, Ruchika (2021-09-25). "BDR Pharma gets DCGI nod for generic antibiotic drug Biapenem". Medical Dialogues. Retrieved 2026-08-04.

[Ubukata_1990-4] 1 2 3 Ubukata K, Hikida M, Yoshida M, Nishiki K, Furukawa Y, Tashiro K, et al. (June 1990). "In vitro activity of LJC10,627, a new carbapenem antibiotic with high stability to dehydropeptidase I". Antimicrobial Agents and Chemotherapy. 34 (6): 994–1000. doi:10.1128/aac.34.6.994. PMC 171745. PMID 2203313.

[5] Goldstein EJ, Citron DM, Tyrrell KL, Merriam CV (June 2013). "In vitro activity of Biapenem plus RPX7009, a carbapenem combined with a serine β-lactamase inhibitor, against anaerobic bacteria". Antimicrobial Agents and Chemotherapy. 57 (6): 2620–2630. doi:10.1128/AAC.02418-12. PMC 3716157. PMID 23529731.

[6] Kozawa O, Uematsu T, Matsuno H, Niwa M, Takiguchi Y, Matsumoto S, et al. (June 1998). "Pharmacokinetics and safety of a new parenteral carbapenem antibiotic, biapenem (L-627), in elderly subjects". Antimicrobial Agents and Chemotherapy. 42 (6): 1433–1436. doi:10.1128/aac.42.6.1433. PMC 105618. PMID 9624490.

[7] Sloan RW (June 1992). "Principles of drug therapy in geriatric patients". American Family Physician. 45 (6): 2709–2718. PMID 1595518.

[8] Perry CM, Ibbotson T (2002). "Biapenem". Drugs. 62 (15): 2221–34, discussion 2235. doi:10.2165/00003495-200262150-00005. PMID 12381221.

[9] Chen HY, Livermore DM (May 1994). "In-vitro activity of biapenem, compared with imipenem and meropenem, against Pseudomonas aeruginosa strains and mutants with known resistance mechanisms". The Journal of Antimicrobial Chemotherapy. 33 (5): 949–958. doi:10.1093/jac/33.5.949. PMID 8089068.

[10] Hara K, Baba S, Matsumoto F, Ooishi M, Kawada Y, Arata J, et al. (November 1999). "[Clinical evaluation of biapenem in various infectious diseases]" Clinical evaluation of biapenem in various infectious diseases. The Japanese Journal of Antibiotics (in Japanese). 52 (11): 629–660. PMID 10659441.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]